Stay updated on Upadacitinib in Active Ankylosing Spondylitis Clinical Trial
Sign up to get notified when there's something new on the Upadacitinib in Active Ankylosing Spondylitis Clinical Trial page.

Latest updates to the Upadacitinib in Active Ankylosing Spondylitis Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedUpdate: publication date changed from August 28, 2025 (Online ahead of print) to August 28, 2025 with the notice removed; the entry now reflects the standard citation without the Online ahead of print note. Core bibliographic details remain the same.SummaryDifference0.2%

- Check27 days agoChange DetectedPage updated to Revision: v3.2.0 from Revision: v3.0.2; indicates a new release version with no other substantive content changes.SummaryDifference0.0%

- Check28 days agoChange DetectedUpdated revision tag from v3.0.2 to v3.1.0. No substantive changes to core content detected.SummaryDifference0.0%

- Check35 days agoChange DetectedRemoved explicit mentions of drug safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs), reducing emphasis on safety/regulatory content.SummaryDifference0.1%

- Check43 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; 'Back to Top' link removed. No substantive content changes detected.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page has been updated to include a new research article on the safety profile of Upadacitinib, and the version has been revised from v3.0.0 to v3.0.1.SummaryDifference1%

Stay in the know with updates to Upadacitinib in Active Ankylosing Spondylitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Upadacitinib in Active Ankylosing Spondylitis Clinical Trial page.